Objectives: Previously, some nitroheteroaryl-1,3,4-thiadiazole derivatives were identified to have potent activity against Leishmania sp. The present aim was to complete the in vitro analysis, thereby investigating the in vivo efficiency of the analogues 15a, 21a and 21b against infected BALB/c mice.
Introduction
Parasitic diseases have an overwhelming impact on public health in developing regions. Many of these infections are caused by protozoan parasites. Malaria, leishmaniasis and trypanosomiasis are the protozoal parasitic diseases that are targeted for control or eradication by the WHO's Division of Control of Tropical Diseases. 1 Leishmaniasis is a complex of diseases caused by ≥17 species of the protozoan parasite Leishmania. Human leishmaniasis is distributed worldwide, but mainly in the tropics and subtropics, with a prevalence of 12 million cases and an approximated incidence of 0.5 million cases of visceral leishmaniasis (VL) and 1.5 million cases of cutaneous leishmaniasis (CL). 2, 3 The chemotherapy currently available for leishmaniasis is far from satisfactory. Resistance to the pentavalent antimonials, which have been the recommended drugs for the treatment of both VL and CL for .50 years, is now widespread throughout the world. 3, 4 Although new drugs have become available in recent years for the treatment of VL, including a highly expensive liposomal formulation of amphotericin B and miltefosine, which has now been registered in India, treatment problems and toxic side effects remain. 3, 5 Cure of leishmaniasis, probably even during chemotherapy, appears to be dependent upon the development of an effective immune response that activates macrophages to produce reactive nitrogen and oxygen metabolites to kill the intracellular amastigotes. The immunomodulator imiquimod has proved to be an adjunct for CL therapy. 5 -7 It has been shown that mammalian host protection against leishmanial infection is dependent on the development of T helper 1 (Th1) responses, which trigger enhanced leishmanicidal activity by infected macrophages. 8 Th1 responses are associated with healing and parasite killing, whereas T helper 2 (Th2) responses are associated with non-healing diseases and uncontrolled parasite growth. Depending on their activation state, macrophages can either host or kill Leishmania. Inducible nitric oxide synthesis (iNOS) and the presence of an oxidative burst are of crucial importance to parasite killing. 11, 12 These pathways are competitively regulated by the cytokines secreted by Th1 and Th2 cells. Experiments have revealed that nitric oxide (NO)-stimulated production by interferon (IFN)-g-activated macrophages is the key effector for killing pathogens, particularly the intracellular parasite Leishmania. Th1 cytokines induce iNOS, which leads to oxidative stress, whereas Th2 cytokines suppress oxidative-inducing pathways. 8, 11, 13, 14 The resolution of infection is mediated by Th1 responses and IFN-g production. IFN-g induces NO production in phagocytic cells that harbour Leishmania major (principally macrophages), which leads to the destruction of the parasite, while BALB/c mice develop Th2 responses, causing severe and uncontrolled lesions to become lethal. All these observations have been attributed to the distinct genetic background of BALB/c mice inducing the Th2 response characterized by elevated levels of interleukin (IL)-4, IL-5 and IL-10. 15 -17 Research in the past two decades has shown that some chemical drugs possess diverse biological and pharmacological properties, such as antioedema, anti-inflammatory, anticarcinogenic, immunomodulatory and antitumour activities. The medicinal values of numerous antimicrobial and anticancer agents have led to them being referred to as immunomodulators, which are biological response modifiers that enhance Th1-and Th2-associated cytokine secretion by spleen cells or macrophages, i.e. they are able to modulate multiple intercellular and intracellular molecular signals involved in the functioning of the immune system. Studies have shown that biological immunomodulators can provide a potent strategy to enhance drug activity in the treatment of VL and CL. Recently, a new generation of immunopotentiating drugs has shown potential for leishmaniasis treatment. One of the imidazoquinolines has been found to induce NO production in macrophages. The compound was shown to have antileishmanial activity via macrophage activation in experimental models and in clinical studies on CL in combination with antimonials. 18 -21 Recent studies have reported the selective cytotoxicity of nitroheteroaryl-1,3,4-thiadiazolebased compounds, including 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines and 1-[5-(5-nitroimidazole-2-yl)-1,3, 4-thiadiazol-2-yl]-4-aroylpiperazines, against Leishmania and a possible molecular mechanism of action for initiating parasite cell death. 22 -24 The aim of the present work was to assess more precisely the in vivo effectiveness and cytotoxicity of the most potent nitroheteroaryl-1,3,4-thiadiazoles.
Materials and methods

Test compounds
All of the nitroheteroaryl-1,3,4-thiadiazole-based compounds, including 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines and 1-[5-(5-nitroimidazole-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines of thiadiazole derivatives ( Figure S1 , available as Supplementary data at JAC Online), tested in this work were synthesized, and the synthesis details, IC 50 s for Leishmania sp. and molecular characterization of the in vitro action were determined previously. 22 -24 Herein, we aimed to identify the in vivo effectiveness of the compounds in infected BALB/c mice, following the instructions described in earlier studies.
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Ethics
We complied with the relevant institutional and national standards for animal care and experimentation. The assay procedures, administration route and doses of the test compounds were selected according to standard operating procedures to cause no pain and distress due to corrosive or severely irritant actions, were approved by Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences and have been described previously. 25 -28 Parasites Promastigotes of L. major (strain MRHO/IR/75/ER; Pasteur Institute, Tehran, Iran) were used in the experiments. The infectivity of the parasites was maintained by regular passaging in susceptible BALB/c mice. The parasites were grown in blood agar cultures at 258C, and recultured at 2×10
6 cells/mL density in RPMI 1640 medium (Sigma-Aldrich Co. LLC, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich Co. LLC, USA), 2 mM glutamine (Sigma-Aldrich Co. LLC, USA), 100 U/mL penicillin and 100 mg/mL streptomycin (Sigma-Aldrich Co. LLC, USA), pH 7.2. For the experiments described here, stationary parasites at the virulence stage were washed three times with PBS and the parasite concentration adjusted to 2×10 7 cells/mL; then, 100 mL was inoculated into 6 -8-week-old BALB/c mice.
Experimental animals
The healthy male BALB/c mice were obtained from the Pasteur Institute, Tehran (Iran). The animals were weighed ( 20 g), housed in groups of eight and screened every day throughout the study.
In vivo activity assessments
The assay procedures, administration route and doses of the test compounds were selected according to the standard operating procedures that have been described previously. 25 -28 All compounds were injected by the intraperitoneal (ip) route, based on previous experience 25 -27 that demonstrated that abdominally administered test compounds have the greatest potential to show activity. The selected standard dosage should be high enough to be effective, but only moderately toxic doses are to be used; the administration of doses that are expected to be lethal or to cause marked pain and distress, due to corrosive or severely irritant actions, should be avoided.
The compounds tested may have a direct effect on the cells of the immune system, as has been demonstrated by in vivo experiments with several drugs; therefore, the lymphocyte-proliferative and cytokine responses of the spleen were examined. 8,29 -31 BALB/c mice infection with L. major, drug administration, lesion monitoring and tissue processing BALB/c mice were infected subcutaneously, via the lateral tail with 2×10 6 stationary-phase promastigotes of L. major in a final volume of 100 mL (in sterile PBS). At 14 days post-infection, after immune granuloma ulcers and skin lesions were observed at the site of injection, the mice were randomly sorted into groups of five and were injected ip with 5 or 20 mg/kg/day doses of the thiadiazole analogues (dissolved in DMSO) for 5 consecutive days. The following treatments were used as controls: treatment with the standard drug meglumine antimoniate (Glucantime), administered ip at 56 mg/kg/day (dissolved in water) for 5 days; injection with 100 mL of DMSO; and no injection. The lesion sizes of the treated and untreated mice were measured regularly with a vernier calliper. The mice were also examined regularly to detect cutaneous ulcers and secondary lesions. At selected timepoints, on days 23 and 30 post-injection, all
Immunomodulatory and leishmanicidal activity examined mice were killed by ether inhalation. The spleens and livers were collected for determination of their parasite loads, histological studies, or both (see below). The livers and spleens were weighed; livers were then immediately fixed in 10% neutral buffered formalin, dehydrated and embedded in paraffin by routine methods for histopathology and parasite infectivity studies. Glass slides with affixed 4 -5 mm thick tissue sections were prepared and stained with haematoxylin and eosin. Spleens were aseptically removed and teased into single-cell suspensions in RPMI medium for limiting dilution analysis, and lymphocyteproliferative and cytokine-response assays, as described above.
Limiting dilution analysis
To evaluate the frequency of L. major-infected cells in the main lymphatic organ, the spleen, groups of mice were killed at intervals after infection and treatment for determination of the parasite burdens. The spleens were excised, weighed and then homogenized with a sterile tissue grinder in 4 mL of RPMI medium prepared as described above. Under sterile conditions, serial 4-fold dilutions ranging from 1 to 12 were prepared in wells of 96-well microtitration plates containing 150 mL of Novy -MacNeal-Nicolle (NNN) culture medium. After 7 and 15 days of incubation at 258C, the plates were examined with an inverted microscope at a magnification of ×100 or ×200. The presence or absence of mobile promastigotes was recorded in each well. The final titre was the last dilution for which the well contained at least one parasite. The number of parasites per gram (parasite burden) in the corresponding organ was calculated as follows: parasite burden¼(geometric mean of reciprocal titres from each duplicate/weight of homogenized cross-section)×400, where 400 is the reciprocal fraction of the homogenized organ inoculated into the first well. 32 
Splenocyte culture and mitogen-induced lymphoproliferative responses
Spleens were aseptically removed and teased into single-cell suspensions in RPMI 1640 supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, 50 mM 2-mercaptoethanol, 2 mM L-glutamine and 10% heat-inactivated FBS. Red blood cells were removed by lysis with 0.83% (w/v) NH 4 Cl. The remaining cells were washed twice with culture medium and the viable mononuclear cell number was determined by counting trypan blue unstained cells in a haemocytometer. Splenocyte suspensions (1×10 7 cells/mL) were dispensed into 96-well culture plates and incubated for 24 h with Salmonella Typhi lipopolysaccharide (LPS; Sigma-Aldrich Co. LLC, USA) at 5 mg/mL as the B cell mitogen or with concanavalin A (ConA; Sigma-Aldrich Co. LLC, USA) as the T cell mitogen; these mitogen concentrations have been shown to induce optimum splenocyte proliferation. After incubation at 378C in 5% CO 2 , the proliferation of spleen cells was measured by colorimetric reading of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduction, as described previously. 33 
Cytokine production by splenocytes
The method used for cytokine production was that described previously. 34 Briefly, as described above, spleen lymphocytes were prepared in RPMI medium. The spleen cell number was adjusted to 1×10 6 cells/mL and cells were cultured in 24-well plates, containing either 10 mg/mL ConA for IFN-g or 10 mg/mL LPS for IL-12/IL-10/IL-5 production, for 72 or 24 h, respectively. After incubation, the lymphocyte culture supernatants were harvested and stored at 2708C for further analysis of cytokine secretion.
Assay for cytokine production by stimulated lymphocytes
Thereafter, culture supernatants were analysed for IFN-g, IL-10 and IL-5 by ELISA (BD Biosciences and R&D Systems, sensitivity 8 -2500 pg/mL), according to the manufacturer's instructions.
Statistical analysis
Student's t-test, with significance at P,0.05, was used to compare the in vivo compound susceptibilities of the parasite.
Results
BALB/c mice inoculated subcutaneously with L. major
The infected mice, inoculated via the base of their tails, developed a detectable lesion (papule or ulcer) during weeks 1 -2. The lesion size progressed steadily to become severe swellings and necrotizing skin lesions at the site of injection. The progression of the lesion was monitored by measuring its length and width at the tail base, until 3-4 weeks after the last drug administration. The control animals that were injected daily with DMSO or 56 mg/kg/day meglumine antimoniate for 5 consecutive days developed larger and necrotizing lesions, which showed progression during the course of infection. In contrast, the daily administration of analogues 15a, 21a and 21b at 5 or 20 mg/kg/day for 5 days resulted in regression and inhibited the development of the lesion. In the first set of experiments (on day 23 postinjection), all control groups (untreated group, meglumine antimoniate treatment and DMSO injection) produced rapidly developing lesions (with lethality in BALB/c mice), which continuously increased in size (lesion size 1.06 -1.44 cm 2 , P,0.05) and showed no signs of recovery ( Figure 1a ). The data presented here indicate that 5 day treatment with 5 mg/kg/day 21b gave greater suppression of lesion development (lesion sizes were 0.14 cm 2 for 21b to 0.657 cm 2 for 21a, P,0.005) in comparison with 20 mg/kg/day doses (lesion sizes were 0.3 cm 2 for 21b to 0.785 cm 2 for 15a, P,0.005); however, with both doses the growth of lesions was greatly controlled and regressed (maximum lesion size 0.785 cm 2 ) ( Figure 1a ). Further, in the second set of experiments (on day 30 post-injection), no sign of parasite regression was observed in the controls, even in the meglumine antimoniate treatments (lesion size 1.7 cm 2 , P,0.005-0.01) (Figure 1b ), whereas thiadiazole treatments demonstrated greater resolution of the lesions, especially with the 5 mg/kg/day doses (lesion sizes were 0.12 cm 2 for 21b and 0.37 cm 2 for 21a, P,0.005) (Figure 1b ). Interestingly, a long time after the last administration of 21a, the cutaneous infection started to regress and the lesion growth was controlled (lesion size 0.37 cm 2 at 30 days post-treatment, which was significantly different from the uninjected and meglumine antimoniate controls, P,0.005, or the DMSO injection controls, P,0.01) (Figure 1b ).
Course pattern of lesion development in drug-treated mice
For better interpretation of the differences in lesion development between the treatment groups, data analysis was conducted, as illustrated in Figure 1(a and b) . Long after exposure of the mice to the analogues 15a, 21a and 21b, following infection with the Pourrajab et al.
parasite, there were similar observations in the cutaneous lesions, correlating with cutaneous Leishmania healing.
Therefore, treatment of BALB/c mice with the test compounds was found to greatly abrogate ulcerated lesions, while in the control groups we observed progression to large lesions. In general, the nitroimidazole analogues 15a and 21a showed a long period of activity against the parasitic infection (Figure 1a and b). Interestingly, untreated, DMSO-injected and meglumine antimoniate-treated mice were not able to control parasite numbers in the lesions, and maintained a large lesion size throughout the period of observation (Figure 1a and b) .
Drug effects and parasite load in spleens of infected BALB/c mice
To investigate if there was a correlation between lesion development and parasite replication in the spleen, the parasite load was estimated using a limiting dilution assay. The animals were killed, spleens weighed and homogenized in 4 mL of RPMI medium, and then plated in 96-well plates containing NNN medium. To assess parasite loads, parasite expansion was observed at weeks 1 and 2 post-treatment. Active VL is characterized by enlargement of the spleen and compromised immunity with increased susceptibility to bacterial superinfections. 35 Five weeks after intradermal injection with the parasite, considerable decreases in spleen weights were observed in the thiadiazole-treated groups, e.g. the smallest spleen weight ( 0.18 g) was related to 21a treatment, which reached a 2-fold decrease in spleen weight (P,0.01) in comparison with the controls; however, enlarged spleens were observed in the meglumine antimoniate-or DMSO-administrated mice (spleen weights 0.33 and 0.39 g, respectively; Figure 2 ). In agreement with cutaneous prevention of lesion development in the thiadiazole analogue-treated mice, small spleens also indicated a prevention of visceral progression of the parasite (Figure 2 ). Likewise, a significant positive correlation (R 2 1) was observed between lesion size and parasite burden in the spleens. In the infection model, typical parasite burdens at days 7 and 14 in the untreated controls were 6857 and 1143, respectively, whereas the 5 and 20 mg/kg/day analogue treatments exhibited parasite burdens of 38 -78 and 14 -145, respectively, at day 7. At day 14, parasite expansions increased, reaching 133 -314 for the 5 mg/kg/day analogue doses and 100 -368 for the 20 mg/kg/day doses, which demonstrated that the parasite's ability to regenerate was very weak. However, outcomes of Immunomodulatory and leishmanicidal activity DMSO and meglumine antimoniate administration showed a marked parasite burden ( 19 000 and 8500) due to the high visceral loading of L. major (Table 1) . In general, all treatments inhibited parasite progression (.90% suppression); in contrast, meglumine antimoniate and DMSO induced positive effects against infection (.24% -180% parasite progression) ( Table 2 ).
Histological suppression of visceral infection induced by L. major in BALB/c mice
Histological studies were performed at 4 and 5 weeks postinfection on livers collected from analogue-treated and untreated (as control) mice. At 30 days post-treatment, the parasite distributions in the livers of control and drug-treated mice were determined ( Figure 3 and Figures S2 to S5 , available as Supplementary data at JAC Online). For each thiadiazole analogue (15a, 21a and 21b), the treatment induced suppression of the parasites in comparison with the control.
Parasites were also abundantly found in the secondary lesions in the liver (Figures 3e and f, S3c, S4 and S5) , attesting to the extensive parasite spreading and visceralization of L. major infection in BALB/c mice; however, this was not observed in analogue-treated mice (Figures 3a-c, S2 and S3a and b). Granuloma-like structures were visible deep in the 5 week postinfection lesions of analogue-treated mice (Figures 3a-c, S2 and S3a and b), but rarely in DMSO-or meglumine antimoniatetreated BALB/c mice (Figures 3d,e, S4 and S5 ). Plasma cells and red pulp were increased in the sinusoids and liver area of both DMSO-and meglumine antimoniate-treated mice (Figures 3f,  S4 and S5). In untreated controls and DMSO-injected mice, follicular hyperplasia of the lymphatic pulp with increased number and size of hepatic nodules appeared in 5 week postinfection lesions of BALB/c mice; also, there was a marked increase in the red pulp area in the sinusoids of meglumine antimoniate-treated mice (Figures 3f and S5) . Vacuolated histiocytes containing parasites were seen in the red pulp in untreated controls, and DMSO-and meglumine antimoniate-treated mice, sometimes forming granuloma-like patterns. In the liver, a portal inflammation with blood cell infiltration and sinusoid dilation was also seen in untreated BALB/c mice. The high density of parasites observed in the red pulp of the liver indicates a bloodstream dissemination of the parasites to other internal organs (Figures 3d-f , S3d, S4d and S5). In contrast, the thiadiazoletreated mice succeeded in eliminating the parasitic infection from the primary cutaneous lesions by the formation of granulomas that healed. Cutaneous fibrosis and granulomatous inflammation were observed, which are associated with the healing process, and the total elimination of parasites from the liver was noted (Figures 3a -c, S2 and S3b).
Thiadiazole analogue-modulated production of Th1-associated cytokines from activated spleen cells Because L. major-infected BALB/c mice present clinical and histopathological features similar to VL in humans, 8 these mice are considered as a putative model for clinical spectrum and immunological studies. The immune response to both forms of leishmaniasis (VL and CL) has been extensively studied in rodent models, and it has been shown that infected macrophages are activated to kill intracellular parasites through elevated levels of reactive oxygen metabolites or NO. 7 -9,11,12,15 -18 This macrophage activation occurs through Th1 responses and the production of cytokines, most critically IFN-g. 9, 10 Infection leads to the down-regulation of these signals and the up-regulation of negative feedback signals, such as IL-10 and 
Enhancement of IFN-g expression in splenocytes of L. major-infected BALB/c mice
Herein, we aimed to identify and validate the stimulatory effects of the compounds on IFN-g, measured 23 days post-injection using ELISA kits specific for the cytokine. We examined the effect of in vivo treatment with thiadiazoles on IFN-g production as an indicator of Th1 activation and macrophage killing of the pathogen (Figure 4 ). The 5 day treatment with 5 mg/kg/day thiadiazole analogue doses significantly (P,0.05) increased the ConA-driven response in comparison with the untreated control (300 -450 versus 150 pg/mL, respectively), while the responses induced by the 20 mg/kg/day doses, meglumine antimoniate and DMSO were similar to those of the control (,150 pg/mL; Figure 4 ). Likely, the enhancement of IFN-g cytokine production in 21b-treated mice may be related to considerable activity against the parasite burden in cutaneous lesions in BALB/c mice. 
major-infected BALB/c mice
We determined the stimulatory effects of the test compounds on IL-10, measured 23 days post-injection. In comparison with 21b, IL-10 Th2-activating cytokine production was significantly suppressed by the analogue 21a, which resulted in a greater reduction of the parasite burden in the liver. Whereas, compound 21b enhanced IFN-g production and thereby regressed lesion size significantly. However, compounds 15a and 21b at 5 mg/kg/day did not considerably affect IL-10 expression (cytokine concentration was 180 -300 pg/mL). Following meglumine antimoniate and DMSO treatment, IL-10 production was measured to be 450 -350 pg/mL ( Figure 5 ). It seems that limiting the IL-10 production was the main mechanism for regressing the parasite-visceral progression in 21a treatments. In general, 20 mg/kg/day treatments increased IL-10 cytokine activity (concentration 350 pg/mL), while reducing IFN-g expression ( Figure 5 ).
Th2 cytokine production of IL-5 by L. major-infected BALB/c mice after thiadiazole treatments IL-5 activity in LPS-stimulated spleen cell cultures was markedly increased by meglumine antimoniate and DMSO treatments (concentration 600 pg/mL in comparison with 180 pg/mL in controls). Th2 indicator cytokine response following the treatments was more than three times greater than measured in control BALB/c mice ( Figure 6 ). IL-5 levels in 5 mg/kg/day thiadiazoletreated mice reached 100 pg/mL, about 1.5 times lower than in infected control mice ( Figure 6 ). However, 20 mg/kg/day thiadiazole treatments did not exhibit favourable results (IL-5 production was 100-300 pg/mL), indicating a possible induction of Th2 activity. Considering the three observations, the thiadiazole analogues were significantly more active at 5 mg/kg/day than at 20 mg/kg/day; therefore, for complete resolution of the parasite, drug administration should be continued. However, the experiment showed that there was no considerable difference for IL-5 cytokine production between the three groups treated with 5 mg/kg/day dose of the compounds (Figure 6 ). Pourrajab et al.
Enhancement of thiadiazole-induced Th1 response in infected BALB/c mice
The degree of drug-induced Th1 immune response was expressed as the stimulation index or index of Th1 activity, which represented the fold increase in Th1-associated cytokine production relative to Th2-associated cytokine production (Figure 7a) . The results represented a 3 -4-fold increase in type-1 immune responses in genetically type-2 competent mice (Figure 7a ). Another stimulation index corresponding to IFN-g/IL-10 in spleen cells was used to express the relation of Th1-to Th2-associated cytokine secretion (Figure 7b ). In comparison with controls, a high level of Th1-related activity was observed in mice treated with 20 and 5 mg/kg/day doses of analogue 21a ( 5-7-fold greater response). Also, type-1-related responses showed 2 -3-fold greater activity following treatment with analogues 15a and 21b (Figure 7b ).
Discussion
Leishmaniasis is a complex of diseases and different clinical forms, which has traditionally been classified in three different clinical degrees: VL, CL and mucocutaneous leishmaniasis, each with different immunopathologies and degrees of morbidity and mortality. 1 The parasite exists in two forms: the flagellated promastigote in the female phlebotomine sand fly vector; and the amastigote in the mammalian host. Amastigotes are obligate intracellular parasites of macrophages (and rarely other cell types), where they survive and multiply within a phagolysosome compartment. 2, 36 The target for chemotherapy is the intracellular amastigote that survives and divides in immune cells, particularly in macrophages, thereby causing coinfection with HIV virus. 37 One of the major aspects in the drug development process for novel antipathogenic agents is the investigation of the chemical -biological interaction in animal models, to obtain lead compounds that can enter the development process. Few of the investigations have been followed by work on the compound in an animal model. 16, 17, 35 Research aimed at identifying and validating new drug targets is important, since the cell biology of Leishmania and mammalian cells differ considerably, and this distinctness extends to the biochemical level. This provides the promise that many of the parasite's proteins should be sufficiently different from anything in the host to be successfully exploited as drug targets. 38 -40 Many potential drug targets have been identified in biochemical and molecular studies, and some have been validated. The search for new drugs continues, with bisphosphonates, e.g. risedronate and pamidronate, and plant derivatives, such as licochalcone A and quinoline alkaloids, being reported to have activity against experimental animal infections. 6 In addition, cure of leishmaniasis during chemotherapy has been shown to depend upon the development of an effective immune response that activates macrophages to produce toxic metabolites, reactive nitrogen species (RNS) and reactive oxygen species (ROS) to kill the intracellular amastigotes. 41, 42 Treatment efficacy is compromised when there is immunosuppression induced by the parasite. This can lead to exacerbation of the disease or emergence from latent infection; the depleted immune capability means that standard chemotherapy is frequently unsuccessful. 43 The immune response to both VL and CL has been extensively studied in rodent models, which has offered paradigms of how cell-mediated immunity activates the infected macrophages to kill the intracellular parasites through elevated levels of ROS and RNS. 41, 42 This is carried out through activation of the correct population of T lymphocytes (Th1) and production of cytokines (IL-12 and IFN-g) to, in turn, activate the macrophages. These factors clearly have implications for chemotherapy. Another competent immune response that is important for effective chemotherapy, of both CL and VL, is extensive granuloma formation around the infected macrophages, which influences the healing induced by the drug. Liver granulomas form by antigen-specific lymphocytes and parasite-specific T cells producing IFN-g that develop type-1 response and compromise the ability of macrophages to kill the parasites. 3, 13, 35 However, these processes are suppressed by the infection itself, which down-regulates the requisite signalling between macrophages and T cells, e.g. the production of IFN-g, up-regulates NO release from IFN-g-activated macrophages, which result in the complete suppression of spleen parasite burden, or the presentation of major histocompatibility complex and costimulatory molecules at the macrophage surface. Studies conducted from Immunomodulatory and leishmanicidal activity the 1980s until now have shown that biological immunomodulators can provide a missing signal and enhance the treatment of VL and CL. 44, 45 The immunomodulatory effects of some drugs with antileishmanial activity have been reported, including their activity as a costimulatory signal for T cell and macrophage activation in vitro, and as an enhancer of IFN-g production and NO in peritoneal macrophages after they are triggered with mitogens. 18, 21, 46 Previously, we reported that nitroheteroaryl-1,3,4-thiadiazolebased compounds, including 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines and 1-[5-(5-nitroimidazole-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines of thiadiazole derivatives, possess potent leishmanicidal activity with selective inhibitory effect against parasite topoisomerase. 22 -24 In this paper, attempts were made to study the in vivo efficacy of the thiadiazole analogues with particular attention to cutaneous lesion size development, visceral progression of the parasite and modulatory effects on murine immune effector cells. We have previously shown that the analogues exerted greater efficiency against the macrophage-intracellular parasite in vitro, possibly through inducing NO and ROS formation (F. Pourrajab, S. K. Forouzannia and S. A. Tabatabaee, unpublished data). Similarly, we also showed that thiadiazoles were non-toxic for mouse macrophage cells at concentrations up to 100 mM. Interestingly, some of the potent thiadiazoles were found to enhance the NO and ROS production pathways inside macrophages and spleen lymphocytes.
The present results for granuloma formation and parasite clearance from the liver are in agreement with an earlier study showing that the compounds could significantly increase macrophage and lymphocyte activity for killing the intracellular parasite. Granulomatose phagocytic cells produce high concentrations of NO and ROS as well as IL-12 and they prime antigenspecific T cells to produce effector cytokines [IFN-g and tumour necrosis factor (TNF)-a]. 9, 14, 42 The resolution of disease in the livers of mice infected with L. major correlates with the local formation of granulomas, which normally form during disease regression in the liver, and are poorly formed in immunodeficient murine and human hosts. Competent immune responses are needed for the successful control of parasite replication in infection sites, as well as to contribute to the induction of leishmanicidal activity within macrophages infected with L. major, as was shown previously in vitro. 22 -24 Parasite-specific CD4+ and CD8+ T cells induce liver granuloma formation and, subsequently, develop Th1-type immune responses. The previous attempts have been followed by the work to establish whether the compound has useful activity against leishmaniasis in an animal model. The results obtained here, may reflect simply that the compounds in the doses injected, show no cytotoxicity for the host, whereas ensuring potent activity to resolving Leishmania infection in an animal model. 35 Moreover, compound-induced type-1 cytokine expression, IFN-g, IL-12 and reduced IL-10 expression in spleen cells in vivo, by stimulating pathways in immune cells, prevents visceral development of the pathogen as well as resolving cutaneous infection and lesion regression by parasite healing. Another report 35 also demonstrated that the production of IL-10 by spleen cells was not induced in the spleens of drug-administrated mice, possibly to balance the effector responses (e.g. oxidative burst) that control the parasite burden in visceral organs and the regulatory cytokines, in order to limit collateral tissue damage due to the increased release of certain cytokines, which result in macrophage and lymphocyte activation. However, the compounds had negative effects on type-2 response by reducing expression of Th2-associated cytokine IL-5, significantly. In our present study, the test compounds could enhance immune response-inducing cytokine production. 
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One speculation is that the analogues might be able to enhance the binding of the mitogen to the receptors so as to achieve the synergistic effect on Th1-associated cytokine production. Another speculation is that the analogues might be able to increase the number of receptors for mitogen binding, thus enhancing immune responses. 47, 48 The finding that the thiadiazole analogues can enhance the effect of mitogens for the activation of spleen cells is not surprising, since an earlier report also demonstrated that some compounds are able to exert immunomodulatory effects in humans to resolve drug-resistant CL. 18 However, the analogues were indicated to induce little IL-10 production and would also down-regulate Th1 response. The apparently contradictory effects might also reflect a differential immunomodulatory efficacy of the drugs to reduce a potentially harmful effect (respiratory burst), thereby reducing the toxic side effects. Actually, the results obtained from the present studies show that the in vivo administration of the new synthetic thiadiazole analogues alone into mice would have no significant cytotoxic effects in vivo and also no potent in vivo efficiency to regress parasite infection; however, they would have an enhancing effect on effector immune cell activation (F. Pourrajab, S. K. Forouzannia and S. A. Tabatabaee, submitted for publication).
Additionally, we observed granuloma formation, which correlates with the local regression of Leishmania infection in mammalian organs. The parasite is controlled within functional granulomas (based on experimental models and the examination of asymptomatic animals). The results demonstrate that the tested compounds can exert in vivo immunomodulatory activity on immune cells to fight against pathogens, whilst inducing no toxicity or visceral damage. In general, we investigated innate and adaptive immune responses to L. major infection in genetically susceptible BALB/c mice, and compared these with responses in drug-administrated mice. The results of our study provide compelling evidence that the selected compounds provide efficient parasite control by innate and adaptive immune responses. Collectively, our findings demonstrate that the analogues can exert immunomodulatory effects on macrophages and lymphocytes, both in vitro and in vivo. Finally, analysis of all the results shows that compound 21a has more effective leishmanicidal activity than the other analogues tested and meglumine antimoniate. The results indicate a need for the clinical applicability of these compounds in the treatment of leishmaniasis to be explored in the future.
A new paradigm in immunology is that conserved microbial structures or pathogen-associated molecular patterns can be recognized by a broad array of host cellular pattern-recognition receptors (TLRs). Such recognition is believed to serve both for the immediate activation of innate immune defences and as a bridge for establishing acquired immunity. 14, 45 As a consequence of TLR recognition, most of these pathogens stimulate the production of inflammatory (TNF-a and IL-12) and/or antiinflammatory (IL-10) cytokines. Also, they prime adaptive immunity through acting on antigen-presenting cells (APCs) or directly engage with T cells and trigger a maturation process in APCs, which endows these cells with an enhanced production of inflammatory cytokines (IL-12) and potent antimicrobial oxidative metabolites as well as the ability to promote Th1-activated cytokine (IFN-g) excretion, which potentiates the immune response severalfold. 9, 45, 47, 48 According to our data, it appears that certain chemical compounds may induce TLR-mediated immunomodulatory effects, in contrast to the parasite exploiting part of this to escape the host's antimicrobial mechanisms. However, there are many questions that remain to be answered regarding TLR-mediated immunomodulatory effects. Also, further studies on the clinical applicability of the compounds are needed, which will allow us to explore the relationship between TLRs and drugs.
